JPWO2023190820A1 - - Google Patents

Info

Publication number
JPWO2023190820A1
JPWO2023190820A1 JP2024512766A JP2024512766A JPWO2023190820A1 JP WO2023190820 A1 JPWO2023190820 A1 JP WO2023190820A1 JP 2024512766 A JP2024512766 A JP 2024512766A JP 2024512766 A JP2024512766 A JP 2024512766A JP WO2023190820 A1 JPWO2023190820 A1 JP WO2023190820A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512766A
Other languages
Japanese (ja)
Other versions
JPWO2023190820A5 (enExample
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023190820A1 publication Critical patent/JPWO2023190820A1/ja
Publication of JPWO2023190820A5 publication Critical patent/JPWO2023190820A5/ja
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2024512766A 2022-03-30 2023-03-30 Pending JPWO2023190820A1 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022055606 2022-03-30
PCT/JP2023/013069 WO2023190820A1 (ja) 2022-03-30 2023-03-30 抗CK2α抗体又はその断片

Publications (2)

Publication Number Publication Date
JPWO2023190820A1 true JPWO2023190820A1 (enExample) 2023-10-05
JPWO2023190820A5 JPWO2023190820A5 (enExample) 2026-04-02

Family

ID=88202747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512766A Pending JPWO2023190820A1 (enExample) 2022-03-30 2023-03-30

Country Status (4)

Country Link
US (1) US20240376227A1 (enExample)
EP (1) EP4403581A4 (enExample)
JP (1) JPWO2023190820A1 (enExample)
WO (1) WO2023190820A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003093056A (ja) * 2001-09-26 2003-04-02 Japan Science & Technology Corp p53のSer46をリン酸化する酵素
CA2501719C (en) * 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
WO2011041785A1 (en) * 2009-10-02 2011-04-07 Cylene Pharmaceuticals, Inc. Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors
WO2012003493A2 (en) * 2010-07-01 2012-01-05 The Regents Of The University Of California Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
EP2472263A1 (en) * 2011-01-03 2012-07-04 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Methods for the prognostic assessment of breast cancer
EP4083627A4 (en) 2019-12-25 2024-01-17 Hoshi General Hospital, a Public Interest Incorporated Foundation PROGNOSTIC BIOMARKER OF CANCER
JP2022055606A (ja) 2020-09-29 2022-04-08 株式会社 Mts雪氷研究所 プログラム及び開口部装置

Also Published As

Publication number Publication date
EP4403581A4 (en) 2025-06-18
EP4403581A1 (en) 2024-07-24
US20240376227A1 (en) 2024-11-14
WO2023190820A1 (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
JPWO2023190820A1 (enExample)
BR202022009269U2 (enExample)
BR202022000931U2 (enExample)
BY13163U (enExample)
BY13165U (enExample)
CN307050370S (enExample)
CN307049997S (enExample)
CN307049449S (enExample)
CN307049367S (enExample)
CN307049261S (enExample)
CN307048460S (enExample)
CN307047953S (enExample)
CN307047661S (enExample)
CN307047555S (enExample)
CN307047179S (enExample)
CN307045506S (enExample)
CN307045322S (enExample)
CN307045286S (enExample)
CN307044911S (enExample)
CN307044782S (enExample)
BY13168U (enExample)
BY13166U (enExample)
BY13164U (enExample)
BY13162U (enExample)
BY13161U (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260325